Who Discovered Rosuvastatin?
Rosuvastatin, the active ingredient in Crestor, was discovered by scientists at Shionogi & Co., a Japanese pharmaceutical company, in the early 1990s. The key inventor credited is Hideo Hagiwara, who led the team that synthesized the compound as part of a mevalonate pathway inhibitor program targeting HMG-CoA reductase.[1]
How Was It Developed?
Shionogi filed the initial Japanese patent in 1991 (JP H05-140153), describing rosuvastatin (then coded as S-4522) among superstatins designed for potency and a favorable safety profile. The team optimized it from earlier pravastatin research, focusing on a pyrimidine-based structure for better cholesterol-lowering efficacy.[2] Development involved collaboration with AstraZeneca, which licensed and commercialized it globally starting in 2003.
Key Patents and Inventors
The primary Japanese patent lists Hideo Hagiwara alongside Masayuki Mizutani, Isao Umeda, and others from Shionogi's research division. International patents, like WO1993004699A1, extend credit to this group. No single "eureka" discoverer stands out; it's team-based innovation typical in pharma.[3] DrugPatentWatch tracks these, noting Shionogi's foundational IP expired around 2010-2016 in major markets.[1]
Licensing and Commercial Path
Shionogi partnered with Zeneca (now AstraZeneca) in 1998 for ex-Asia rights. AstraZeneca handled late-stage trials, FDA approval in 2003, and marketing as Crestor. Shionogi retained rights in Japan and parts of Asia.
Related Discoveries in Statins
Rosuvastatin built on Sankyo's compactin (1980, first statin) and Merck's lovastatin (1987). Shionogi's edge was higher potency at lower doses, reducing myopathy risks compared to predecessors like simvastatin.[4]
[1]: DrugPatentWatch.com - Rosuvastatin Patents
[2]: Shionogi Patent JP H05-140153
[3]: WO1993004699A1 - Pyrimidine Derivatives
[4]: Nature Reviews Drug Discovery - Statin History